FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/03/2025
Back to search
Official data from USPTO
ELASMOGEN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ELASMOGEN
ST13
US500000079379490Class
5, 42, 44
Filing
79379490
Registration
7567642
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
04/03/2026
Trademark type
Word
Nice classes
5, 42, 44
Filing date
04/19/2023
Registration date
11/19/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/19/2024
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
GB
Examiner
MICKLEBURGH, LINDA BOHANNON
Law office
L60
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Elasmogen Ltd
Representatives
Charlene M. Krogh Dorsey & Whitney LLP
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for treatment of cancerinflammatory diseasesauto-inflammatory diseasesautoimmune diseases and eye diseases and disorders; biological preparations for treatment of cancerinflammatory diseasesauto-inflammatory diseasesautoimmune diseases and eye diseases and disorders; diagnostic preparations agentssubstances for medical purposes; anti-angiogenesis preparations; anti-cancer preparations; anti-inflammatory preparations; pharmaceutical and biochemical preparations for the treatment or prevention of cancerinfectious diseasephysiological disordershormonal disordersinherited diseasesingle gene disordersrespiratory diseasesgastro-intestinal disorderscirculatory disordersdermatological conditionsimmuno-deficienciesorgan damagecell proliferationperipheral neurological disordersgenitourinary disordersmusculoskeletal disordersblood disorders; diagnostic reagents for medical use; DNAantibodies and proteins for medical diagnosis purposes; DNA and antibodies and proteins that stimulate cells for medical use; DNAantibodies and proteins for therapeutic use for treatment of cancerinflammatory diseasesauto-inflammatory diseasesautoimmune diseases and eye diseases and disorders; diagnostic preparations for medical purposes; reagents for medical use
Class 42
Medical and pharmacological research services; scientific and technological servicesnamely scientific researchanalysis and testing in the field of cancerinflammatory diseasesauto-inflammatory diseasesautoimmune diseaseseye diseases and disordersintracellular delivery of pharmaceuticals and therapeutics; scientific research for medical purposes in the field of cancerinflammatory diseasesauto-inflammatory diseasesautoimmune diseaseseye diseases and disordersintracellular delivery of pharmaceuticals and therapeutics; pharmaceutical research and drug development services; pharmaceutical testing; research and development in the biotechnology field; research and development services in the field of antibodies; biotechnology research services; scientific research in the nature of conducting clinical trials for others; biological researchclinical research and medical research; providing scientific information about the results of clinical trials for pharmaceutical products; research services in the field of diagnostic preparations; scientific laboratory services; custom design and development of biochemical assays; scientific and medical research laboratory services; research and development of new products for others; scientific research and analysis in the field of drug discovery; new product development in the field of pharmaceuticals for others; scientific advisory servicesmedical advisory services related to pharmaceutical development and testing; scientific research consultancy in the field of cancer researchinflammatory disease researchauto-inflammatory disease researchautoimmune disease researcheye disease and disorder researchintracellular delivery research of pharmaceuticals and therapeutics; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals; consulting services for others in the field of designplanningimplementation and project management of scientific research and clinical trials; providing scientific research information; technical advisory services relating to scientific and clinical research; provision of technical and scientific information and consultancy in relation to the aforesaid services.
Class 44
Medical services; medical advisory services relating to the treatmentrelief and prevention of cancerinfectious diseasephysiological disordershormonal disordersinherited diseasesingle gene disordersrespiratory diseasesgastro-intestinal disorderscirculatory disordersdermatological conditionsimmuno-deficienciesorgan damagecell proliferationperipheral neurological disordersgenitourinary disordersmusculoskeletal disordersblood disorders; preparation and provision of medical reports to patients and medical professionals; preparation and provision of medical information in the form of reports on pharmaceuticalsadvanced therapy medicinal productstherapeutic antibodies to patients and medical professionals; consultancyadvice and information in the field of healthcarepharmaceuticals and advanced therapy medicinal products
Publications
History of USPTO decisions and trademark events.
25 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/16/2025
FIMP
FINAL DISPOSITION PROCESSED
04/16/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/14/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/27/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
02/27/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/19/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/19/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
11/19/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/03/2024
PUBO
PUBLISHED FOR OPPOSITION
09/03/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/14/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/31/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/29/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/29/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/29/2024
RFNT
REFUSAL PROCESSED BY IB
02/19/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/01/2024
RFRR
REFUSAL PROCESSED BY MPU
02/01/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/18/2024
CNRT
NON-FINAL ACTION WRITTEN
01/17/2024
DOCK
ASSIGNED TO EXAMINER
01/17/2024
MAFR
APPLICATION FILING RECEIPT MAILED
10/03/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/29/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/28/2023
Continuous trademark protection
Get notified about every new filing that threatens ELASMOGEN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.